137 related articles for article (PubMed ID: 8546383)
21. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
Egan MA; Chong SY; Rose NF; Megati S; Lopez KJ; Schadeck EB; Johnson JE; Masood A; Piacente P; Druilhet RE; Barras PW; Hasselschwert DL; Reilly P; Mishkin EM; Montefiori DC; Lewis MG; Clarke DK; Hendry RM; Marx PA; Eldridge JH; Udem SA; Israel ZR; Rose JK
AIDS Res Hum Retroviruses; 2004 Sep; 20(9):989-1004. PubMed ID: 15585086
[TBL] [Abstract][Full Text] [Related]
23. Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env.
Ensoli B; Cafaro A; Caputo A; Fiorelli V; Ensoli F; Gavioli R; Ferrantelli F; Cara A; Titti F; Magnani M
Microbes Infect; 2005 Nov; 7(14):1392-9. PubMed ID: 16243561
[TBL] [Abstract][Full Text] [Related]
24. Gene therapy clinical trials for HIV.
Statham S; Morgan RA
Curr Opin Mol Ther; 1999 Aug; 1(4):430-6. PubMed ID: 11713756
[TBL] [Abstract][Full Text] [Related]
25. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
Earl PL; Wyatt LS; Montefiori DC; Bilska M; Woodward R; Markham PD; Malley JD; Vogel TU; Allen TM; Watkins DI; Miller N; Moss B
Virology; 2002 Mar; 294(2):270-81. PubMed ID: 12009868
[TBL] [Abstract][Full Text] [Related]
26. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84.
DePalma L
Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387
[No Abstract] [Full Text] [Related]
27. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine.
Fuller DH; Haynes JR
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1433-41. PubMed ID: 7888198
[TBL] [Abstract][Full Text] [Related]
28. Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses.
Xin KQ; Ooki T; Mizukami H; Hamajima K; Okudela K; Hashimoto K; Kojima Y; Jounai N; Kumamoto Y; Sasaki S; Klinman D; Ozawa K; Okuda K
Hum Gene Ther; 2002 Sep; 13(13):1571-81. PubMed ID: 12228012
[TBL] [Abstract][Full Text] [Related]
29. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946).
Kundu-Raychaudhuri S; Sevin A; Kilgo P; Nokta M; Pollard RB; Merigan TC
AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1371-8. PubMed ID: 11679149
[TBL] [Abstract][Full Text] [Related]
30. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
Quinnan GV; Yu XF; Lewis MG; Zhang PF; Sutter G; Silvera P; Dong M; Choudhary A; Sarkis PT; Bouma P; Zhang Z; Montefiori DC; Vancott TC; Broder CC
J Virol; 2005 Mar; 79(6):3358-69. PubMed ID: 15731230
[TBL] [Abstract][Full Text] [Related]
31. The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance.
Liem SE; Ramezani A; Li X; Joshi S
Hum Gene Ther; 1993 Oct; 4(5):625-34. PubMed ID: 8280800
[TBL] [Abstract][Full Text] [Related]
32. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of humoral immunity to SIVenv following simultaneous inoculation of mice by three recombinant adenoviruses encoding SIVenv/poliovirus chimeras, Tat and Rev.
Chenciner N; Randrianarison-Jewtoukoff V; Delpeyroux F; Hanania N; Pedroza Martins L; Stratford Perricaudet L; Perricaudet M; Wain-Hobson S
AIDS Res Hum Retroviruses; 1997 Jun; 13(9):801-6. PubMed ID: 9171225
[TBL] [Abstract][Full Text] [Related]
34. Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef.
Patterson LJ; Malkevitch N; Zhao J; Peng B; Robert-Guroff M
DNA Cell Biol; 2002 Sep; 21(9):627-35. PubMed ID: 12396605
[TBL] [Abstract][Full Text] [Related]
35. Long-term maintenance of gp120-specific immune responses by genetic vaccination with the HIV-1 envelope genes linked to the gene encoding Flt-3 ligand.
Sailaja G; Husain S; Nayak BP; Jabbar AM
J Immunol; 2003 Mar; 170(5):2496-507. PubMed ID: 12594275
[TBL] [Abstract][Full Text] [Related]
36. Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates.
Irwin MJ; Laube LS; Lee V; Austin M; Chada S; Anderson CG; Townsend K; Jolly DJ; Warner JF
J Virol; 1994 Aug; 68(8):5036-44. PubMed ID: 8035504
[TBL] [Abstract][Full Text] [Related]
37. The immune response to HIV gp120 induced by nucleic acid immunization (NAI).
Peet N; Delves PJ; de Souza B; Cambridge G; Wilkinson L; Klonisch T; Matear P; Vyakarnam A; Lund T
Ann N Y Acad Sci; 1995 Nov; 772():257-60. PubMed ID: 8546402
[No Abstract] [Full Text] [Related]
38. Accell particle-mediated DNA immunization elicits humoral, cytotoxic, and protective immune responses.
Haynes JR; Fuller DH; Eisenbraun MD; Ford MJ; Pertmer TM
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S43-5. PubMed ID: 7865332
[TBL] [Abstract][Full Text] [Related]
39. Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C.
Barnett SW; Srivastava IK; Ulmer JB; Donnelly JJ; Rappuoli R
Microbes Infect; 2005 Nov; 7(14):1386-91. PubMed ID: 16275150
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
